Direct evidence connecting this effect to HH signaling is evident in AML, where cells treated with SMO inhibition (glasdegib) showed significantly fewer dormant CD45+ cells and were sensitized to Ara-C treatment (84). This evidence concerns the gene SMO and acute myeloid leukemia.